Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.

Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, Riely GJ.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003665. doi: 10.1101/mcs.a003665. Print 2019 Apr.

2.

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.

PMID:
29991499
3.

Mentoring Hispanic undergraduate and graduate research assistants: building research capacity in nursing.

Aponte J, Figueroa BN, Madera M, Campos-Dominguez G, Panora E, Jaramillo D.

J Nurs Educ. 2015 Jun;54(6):328-34. doi: 10.3928/01484834-20150515-03.

PMID:
26057426

Supplemental Content

Loading ...
Support Center